Clinical trials: Primary Malignant Brain Tumor
Anaplastic Astrocytoma, Diffuse Brainstem Glioma
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Recent advances in technology have allowed for the detection of cell-free DNA (cfDNA). cfDNA is tumor DNA that can be found in the fluid that surrounds the brain and spinal cord (called cerebrospinal fluid or CSF) and in the…
- Conditions
- Anaplastic Astrocytoma, Diffuse Brainstem Glioma, Glioblastoma Multiforme, High-grade Astrocytoma NOS
- Trial name
- NCT05934630
- Where
- 10 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
Central Nervous System Cancer, Brain Metastases
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months…
- Trial name
- NCT07462507
- Testing
- [C-11]-CS1P1, Brain MRI
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Washington University School of Medicine
Brain Tumor
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
- Trial name
- NCT03220646
- Testing
- abemaciclib
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Brain Tumor, Primary
Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease.
- Trial name
- NCT06185686
- Testing
- Cognitive testing, Resting State MRI/Precision functional mapping
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Glioma, Mixed, Mild Neurocognitive Disorder
C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors
The goal of Phase Ib Trial is to determine the feasibility and acceptability of telehealth C-SMART for patients with primary brain tumor and mild neurocognitive deficits (N=18) and their caregivers (N=14) A subset (n=3) of…
- Conditions
- Glioma, Mixed, Mild Neurocognitive Disorder, Brain Tumor
- Trial name
- C-SMART (NCT05984667)
- Testing
- C-SMART
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Virginia Commonwealth University
Glioma, Primary Brain Tumor
MRI-based Computer Aided Diagnosis Software (V1) for Glioma
The goal of this multi-center clinical trial is to evaluate the effectiveness of MRI-based computer-aided diagnosis software (V1) for glioma segmentation, gene prediction, and tumor grading.
- Trial name
- NCT05739500
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Mingge LLC
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
High Grade Glioma, Meningioma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET.
- Conditions
- High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma
- Trial name
- NCT05278208
- Testing
- LUTATHERA® (Lutetium Lu 177 dotatate)
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nationwide Children's Hospital
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Brain Neoplasms, Malignant, Primary
Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference…
- Trial name
- NCT02343081
- Testing
- Temozolomide
- Where
- 2 sites in Argentina
- Volunteers
- 24 people
- Sponsor
- Monte Verde SA
Glioblastoma
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
- Trial name
- NCT00616005
- Testing
- Temodar and Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Glioblastoma, Glioma
Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients With Brain Lesions.
Neurovascular uncoupling (NVU) represents a major source of potential bias for the identification of eloquent brain regions through activation procedures in blood oxygen level dependent (BOLD) functional magnetic resonance…
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- NVUCVR (NCT06797661)
- Testing
- Functional MRI, FDG-PET, Structural MRI
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Erasme University Hospital
Brain Metastases, Bone Metastases
Comparing Immobilisation Shells in Cranial Radiotherapy
Patients having radiotherapy to their head and neck wear an immobilisation shell to prevent patient movement and improve treatment accuracy.
- Conditions
- Brain Metastases, Bone Metastases, Brain Tumor, Primary, Brain Tumor Adult
- Trial name
- CORIOLIS (NCT02599142)
- Testing
- Group A: Closed-face shell, Group B: Open-face shell
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Brain Neoplasms, Primary Malignant
Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers
The purpose of this study is to explore the experiences and needs of patients with a high-grade glioma and their caregivers. Semi-structured interviews with patients and caregivers will be conducted and analysed using…
- Trial name
- NCT01638130
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Glioblastoma, High-grade Glioma
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients.
- Conditions
- Glioblastoma, High-grade Glioma, Glioblastoma, IDH-wildtype, Glioblastoma, IDH-mutant
- Trial name
- SUPRAMAX (NCT06118723)
- Testing
- Supramaximal resection, Maximal safe resection
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 784 people
- Sponsor
- Jasper Gerritsen
Brain and Central Nervous System Tumors
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003564
- Testing
- Isotretinoin, Procarbazine Hydrochloride
- Sponsor
- M.D. Anderson Cancer Center
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Brain Neoplasms, Malignant Neoplasms, Brain
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.
- Conditions
- Brain Neoplasms, Malignant Neoplasms, Brain, Brain Tumors
- Trial name
- NCT00062478
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Mood, Cancer Brain
Managing Cancer and Living Meaningfully
The purpose of this study is to pilot test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM).
- Trial name
- CALM (NCT04646213)
- Testing
- Managing Cancer and Living Meaningfully (CALM) Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University